Revenue Update on Catalent Inc(NYSE:CTLT)

Catalent Inc(NYSE:CTLT) announced the earnings results for Fiscal Year 2017 and Q2. The results came in during After-Market on Feb 6, 2017. Company reported revenue of $483.700M. Analysts estimated a revenue of $474.070M. The revenues were 2.03% above the estimates. Earnings per share were $0.27. The reported EPS was above estimates by 3.85%. Analysts had estimated an EPS of $0.26.

Catalent Inc (CTLT) made into the market gainers list on Tuesdays trading session with the shares advancing 1.36% or 0.38 points. Due to strong positive momentum, the stock ended at $28.36, which is also near the day’s high of $30.22. The stock began the session at $29.29 and the volume stood at 14,94,034 shares. The 52-week high of the shares is $32.24 and the 52 week low is $18.92. The company has a current market capitalization of $3,539 M and it has 12,47,76,012 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at $28.85 per share price.Also, On Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price.On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price, according to the Form-4 filing with the securities and exchange commission.

Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.

Share this post

Leave a Reply